Research programme: monoclonal antibodies against MERS - Regeneron/Sanofi

Drug Profile

Research programme: monoclonal antibodies against MERS - Regeneron/Sanofi

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Middle East respiratory syndrome coronavirus

Most Recent Events

  • 22 Aug 2016 Regeneron Pharmaceuticals enters into a collaboration agreement with Sanofi to develop human monoclonal antibodies for Middle East respiratory syndrome coronavirus before August 2016
  • 22 Aug 2016 Regeneron receives grant from Biomedical Advanced Research and Development Authority (BARDA) for antibody drug candidates development in Middle East respiratory syndrome coronavirus
  • 22 Aug 2016 Regeneron announces intention to submit IND to US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top